Munro Aime, Codde Jim, Semmens James, Leung Yee, Spilsbury Katrina, Williams Vincent, Steel Nerida, Cohen Paul, Pavicic Heidi, Westoby Vicki, O'Leary Peter
BExSc, MSc, PhD Candidate, Senior Program Officer (Research), WA Cervical Cancer Prevention Program, Perth, WA.
Aust Fam Physician. 2015 Jan-Feb;44(1-2):64-8.
Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount.
After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology.
Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear follow-up plan for patients after treatment of an HSIL.
GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.
接受高级别鳞状上皮内病变（HSIL）治疗的患者发生持续性/复发性宫颈疾病的风险增加。因此，了解全科医生（GPs）是否充分利用联合检测（人乳头瘤病毒[HPV]DNA检测和宫颈细胞学检查）至关重要。
在与关键利益相关者协商后，制定了一份匿名的自填式问卷，并分发给提供过宫颈细胞学检查的全科医生。
共收到745名全科医生的回复（回复率为30.9%）。相当数量（34.3%）的全科医生不知道在HSIL治疗后使用联合检测（HPV DNA检测和宫颈细胞学检查）来管理患者。此外，大多数全科医生报告称，在HSIL治疗后，他们并非“总是”收到针对患者的明确随访计划。
全科医生需要进一步的支持和教育，以确保成功采用联合检测（HPV DNA检测和宫颈细胞学检查），特别是对于接受HSIL治疗的患者。
